

Percutaneous Bypass: Rebirth as Treatment for CTO

Alan C.Yeung, MD



UC200402587 EN For use by Medtronic Vascular personnel only. Do not copy or distribute.

Percutaneous Bypass Procedures Under Development for the Last 5 years

- Percutaneous In-Situ Coronary Venous Arterialization (PICVA)
- Percutaneous In-Situ Coronary Artery Bypass (PICAB)



PICVA - Basic Concept

Percutaneous In-Situ Coronary Venous Arterialization

- Anastomosis made between diffusely diseased coronary artery and adjacent vein
- Venous egress to coronary sinus is blocked
- Arterial blood then perfuses myocardium retrograde through distal vein





PICAB Basic Concept

Percutaneous In-Situ Coronary Artery Bypass

- Coronary vein acts as "jump" bypass graft
- Two anastomoses made percutaneously
- Vein isolated percutaneously





PICVA Clinical Experience

- Clinical Target
 - No-Option Patients With Class III/IV Angina
 - Viable Ischemic Target In Anterior/Septal Area
- Initial Trial Suspended 2002
 - IVUS-based TransAccess, Self-expanding Occluder
 - 11 Patients Enrolled, 5 completed procedures
 - 2 deaths led to voluntary trial suspension to revise devices
- Trial Re-Initiated 2003
 - NOGA-based TransAccess, Balloon-expandable Occluder
 - 1 Patient Enrolled, Successfully Treated Milan [Colombo]
 - TCT follow-up, Channel closed

Lessons learned

- Difficult procedure in best of hands
- Arterial to Venous anatomy unpredictable
- Venous blocker size changes with higher pressure load condition (may continue to change)
- AV connector needs to be covered and drug eluting



Coronary True Lumen Return (TLR)

- CTO Target Population
 - 10 20% of all angiographic cases
 - 80% of all failed angioplasty
- More CTOs will be intervened on with the availability of Drug Eluting Stents
- Subintimal Wire Trapping
 - Approx 20 40% of all CTO attempts
 - Remains the major failure mode for new approaches [Lumend, Intraluminal Therapeutics, New Wires]



Coronary True Lumen Return

- CrossPoint® TransAccess
 - 2 mm Tip
 - 6.2 Fr Shaft
 - Requires 9 Fr Guide

- Coronary TLR TransAccess
 [under development]
 - 1.2 mm Tip
 - 5 Fr Shaft w/ 4 Fr Distal Shaft
 - Requires 8 Fr Guide





Subintimal CrossPoint[®] IVUS Image



CrossPoint® Catheter IVUS image from within a dissection of the SFA



CrossPoint[®] Catheter

Key Features:

- 24G needle allows for delivery of a 0.014" guidewire
- Flexible shaft allows for contralateral approach
- 7F Introducer sheath compatibility (0.087" I.D.)
 - Exception: Compatible with Medtronic 6F Input PS Sheath





CrossPoint[®] Catheter

Key Features:

- 6.9F catheter tracks over 0.014" guidewire.
- Catheter length: 120cm
- Integrated 64-element, phased array IVUS with 20 MHz transducer.*



 Solid state versus mechanical

* For use with the Volcano/JOMED In-Vision IVUS console





True Lumen Return Step 1: Guide Wire Entrapment





True Lumen Return Step 2: Catheter Insertion





True Lumen Return Step 2: Catheter Insertion

Using an exchange catheter. exchange the 0.035" wire for 0.014" extra-support HTF guide wire (190cm);

Pass CrossPoint catheter over subintimal guidewire*.



*Note: DO NOT use the CrossPoint catheter without a guide wire in place. Heavily calcified vessel wall may require small 20 mm diameter balloon dilation prior to CrossPoint catheter use. The CrossPoint catheter is not intended to be used as a <u>tunneling device through</u> a total occlusion.



1. Using IVUS componentorient catheter toward true lumen by rotating the entire catheter.

2. Verify position with fluoro.









Orient catheter toward true lumen

 Rotate CrossPoint catheter using ChromaFlo and 'comet tail' as guide*.

*Note: Comet tail will remain in 12:00 position and anatomy will rotate. Rotate the catheter no more than 180° in clockwise or counterclockwise direction. Change direction as required.







Platinum iridium needle housing ______ facilitates catheter orientation toward true lumen





True Lumen Return Step 4: Deploy Needle





True Lumen Return Step 5: Pass Guide Wire

Pass 0.014" extra-support guide wire (300cm) through CrossPoint needle into vessel lumen.

Note: The needle may need to be withdrawn slightly in order to advance the guide wire. DO NOT use plastic or hydrophilic coated wires.





True Lumen Return Step 6: Remove the CrossPoint





True Lumen Return Step 7: Treat the Vessel

Treat the vessel with a PTA balloon and/ or with stent placement.





True Lumen Return: Controlled Re-entry: Case Presentation



UC200402587 EN For use by Medtronic Vascular personnel only. Do not copy or distribute.



Figure 1 and 2: Total occlusion of the left SFA with dense calcification







Figure 3 and 4: LuMend's Frontrunner® CTO Catheterunable to cross calcified lesion



Figure 3







Figure 6

Figure 7

Figure 5: Guidewire subintimal Figure 6: CrossPoint catheter around bifurcation

Figure 7: CrossPoint catheter in subintimal space









Figure 8: IVUS image for needle deployment Figure 9: Needle deployed

Figure 10: Guidewire into true lumen





Before





Myocardial Delivery Devices





Myocardial Repair

TransAccess[®] Delivery System





UC200402587 EN

TransAccess® Delivery System

• TransAccess[®] Catheter

- 6.2F Catheter with Integrated IVUS
- Tracks over .014 Guide Wire
- Pre-Shaped 24G Nitinol Needle

• IntraLumeTM Microcatheter

- 27G Injection Catheter
- Delivered Through TransAccess Needle
- Radiopaque Beveled Tip





Pre-Clinical Testing: Efficiency and Retention

- Erasmus University Study
 - Porcine model
 - N = 4 Animals
 - N = 10 injections total
 - TC⁹⁹-labelled VEGF₁₆₅

PCR 2002 by P. Smits with data obtained via same protocol from AHA Abstract entitled "Efficiency Between a NOGA and a Fluoroscopy Guided Transendomyocardial Injection Catheter," AHA Abstract: Scientific Conference On Therapeutic Angiogenesis & Myocardial Laser Revascularization, Jan. 2001





Potential Advantages Over Endocardial Approaches

- Long, contiguous tracks
 - (2-6 cm, rather than 2-6 mm)
- Lower bleedback creates higher injection efficiency
- Any injection losses go into venous return, rather than bleedback into arterial circulation
- Access to entire left ventricle





Pre-Clinical Validation - Contiguous Tracts -



• **Thompson et al.** Percutaneous transvenous cellular cardiomyoplasty: A novel nonsurgical approach for myocardial cell transplantation. J Am Coll Cardiol, 2003, 41:11.

